LitCovid-sentences  

PMC:7127386 / 8309-11421 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T46 0-79 Sentence denotes Table 1 Antiviral activity of 16 compounds against SARS-CoV-2 in Vero E6 cells.
T47 80-127 Sentence denotes Compounds Inhibition of SARS-CoV-2 in vitro, μM
T48 128-173 Sentence denotes Name Bioactivity Clinical application CAS No.
T49 174-273 Sentence denotes CC50, μMa CPE inhibitionb Reduction in infectious virusc (EC50) Reduction in viral RNA copyd (EC50)
T50 274-388 Sentence denotes Remdesivir adenosine analogue Phase 4 trials for treatment of Ebola or SARS-CoV-2 1809249-37-3 >100 25 23.15 26.90
T51 389-513 Sentence denotes Favipiravir guanineanalogue Approved in Japan and China for treatment of influenza infection 259793-96-9 >100 >100 >100 >100
T52 514-632 Sentence denotes Ribavirin guanosine analogue FDA approved for treatment of chronic hepatitis C infection 36791-04-5 >100 500 >500 >500
T53 633-741 Sentence denotes Galidesivir adenosine analogue Phase 2 trial for yellow fever virus infection 222631-44-9 >100 100 >100 >100
T54 742-846 Sentence denotes R-1479 cytidineanalogue Phase 2 trial for treatment of dengue virus infection 478182-28-4 >100 >100 N.D.
T55 847-851 Sentence denotes N.D.
T56 852-951 Sentence denotes Tenofovor adenosine analogue FDA approved for treatment of HIV-1 and HBV 147127-20-6 >100 >100 N.D.
T57 952-956 Sentence denotes N.D.
T58 957-1089 Sentence denotes Fludarabine phosphate adenosine analogue FDA approved for treatment of B-cell chronic lymphocytic leukemia 75607-67-9 >100 >100 N.D.
T59 1090-1094 Sentence denotes N.D.
T60 1095-1232 Sentence denotes Lopinavir protease inhibitor FDA approved for treatment of HIV-1 infection in combination with ritonavir 192725-17-0 49.75 25 26.63 26.10
T61 1233-1388 Sentence denotes Ritonavir protease inhibitor FDA approved for treatment of HIV-1 infection in combination with other antiretroviral agents 155213-67-5 48.91 >100 >100 >100
T62 1389-1506 Sentence denotes Emetine hydrochloride anti-protozoal Approved in China for severe invasive amoebiasis 316-42-7 56.46 1.5625 0.46 0.50
T63 1507-1644 Sentence denotes Oritavancin diphosphate antibiotics FDA approved treatment for skin infection caused by Gram positive bacteria 192564-14-0 N.D. >100 N.D.
T64 1645-1649 Sentence denotes N.D.
T65 1650-1790 Sentence denotes Dalbavancin hydrochloride antibiotics FDA approved treatment for skin infection caused by Gram positive bacteria 2227366-51-8 N.D. >100 N.D.
T66 1791-1795 Sentence denotes N.D.
T67 1796-1910 Sentence denotes Homoharringtonine anti-cancer FDA approved treatment for chronic myeloid leukemia 26833-87-4 59.75 3.125 2.55 2.14
T68 1911-2048 Sentence denotes Oseltamivir carboxylate antiviral, neuraminidase inhibitor FDA approved treatment for influenza infection 187227-45-8 >100 >100 >100 >100
T69 2049-2178 Sentence denotes Baloxivir acid antiviral, endonuclease inhibitor FDA approved treatment for influenza infection 1985605-59-1 85.90 >100 >100 >100
T70 2179-2311 Sentence denotes Chlorpromazine hydrochloride antagonist for post-synaptic receptors FDA approved treatment for schizophrenia 69-09-0 21.29 >100 N.D.
T71 2312-2316 Sentence denotes N.D.
T72 2317-2321 Sentence denotes N.D.
T73 2322-2337 Sentence denotes Not determined.
T74 2338-2497 Sentence denotes a CC50 was determined with serially-diluted compounds in Vero E6 cells at 48 h post-incubation using CellTiter-Glow Luminescent Cell Viability Assay (Promega).
T75 2498-2607 Sentence denotes b Compounds were serially 2-fold or 4-fold diluted from 100 μM, except ribavirin which was started at 500 μM.
T76 2608-2755 Sentence denotes Cytopathic effects (CPE) of SARS-CoV-2 virus in Vero E6 cells under increasing concentration of the compounds were observed at 48 h post-infection.
T77 2756-2892 Sentence denotes The lowest concentration of the compound with 100% CPE inhibition (eg. exhibiting comparable CPE of non-infected controls) was recorded.
T78 2893-3000 Sentence denotes c EC50 determined by infectious virus yield in culture supernatant at 48h post-infection (log10 TCID50/mL).
T79 3001-3112 Sentence denotes d EC50 determined by viral RNA copy numbers in culture supernatant at 48h post-infection (log10 RNA copies/mL).